Edition:
United Kingdom

Versartis Inc (VSAR.OQ)

VSAR.OQ on NASDAQ Stock Exchange Global Select Market

1.55USD
20 Apr 2018
Change (% chg)

$-0.03 (-1.59%)
Prev Close
$1.58
Open
$1.55
Day's High
$1.60
Day's Low
$1.55
Volume
28,553
Avg. Vol
80,209
52-wk High
$22.10
52-wk Low
$1.52

Chart for

About

Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company's first indication for somavaratan is pediatric GHD. The Company may develop... (more)

Overall

Beta: 2.07
Market Cap(Mil.): $55.91
Shares Outstanding(Mil.): 36.07
Dividend: --
Yield (%): --

Financials

  VSAR.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -3.33 -- --
ROI: -98.62 -0.74 13.19
ROE: -100.91 -2.80 15.00

BRIEF-Versartis Q4 Earnings Per Share $0.87

* VERSARTIS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

01 Mar 2018

BRIEF-Advent Life Sciences Reports 4.5 Pct Passive Stake In Versartis Inc

* ADVENT LIFE SCIENCES LLP REPORTS A 4.5 PERCENT PASSIVE STAKE IN VERSARTIS, INC. AS OF DEC 31, 2017 - SEC FILING Source text - http://bit.ly/2EuDXO8 Further company coverage:

08 Feb 2018

BRIEF-Versartis Inc Says Board Appointed Jay Shepard, CEO, To Position Of Principal Financial Officer

* VERSARTIS INC SAYS ‍ON NOV 28, 2017, BOARD APPOINTED JAY SHEPARD, CEO, TO POSITION OF PRINCIPAL FINANCIAL OFFICER, EFFECTIVE DEC 1, 2017 - SEC FILING​ Source text (http://bit.ly/2A3BTve) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

04 Dec 2017

BRIEF-Versartis hires Cowen to assist in evaluating potential strategic transactions

* Versartis hires Cowen to assist in evaluating potential strategic transactions

26 Oct 2017

BRIEF-Versartis reports Q3 loss $1.40/shr

* Versartis reports third quarter 2017 financial results and provides corporate update

26 Oct 2017

Earnings vs. Estimates